Shadia Zaman - Concepedia

Author

Shadia Zaman

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

S Zaman, Shadia Zaman, Zaman, Shadia

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center University of Michigan Princeton University Center for Drug Evaluation and Research The University of Texas Health Science Center at Houston

About

Shadia Zaman is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, signal transduction, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	633
2	Cell Biology	4	4	599
3	Natural Sciences	1	1	235
4	Public Health	1	1	23
5	Epidemiology	1	1	23

Shadia Zaman

Publications

809

Citations

H-Index

Page 1

	Year	Citations
Protein Kinase A and Sch9 Cooperatively Regulate Induction of Autophagy in<i>Saccharomyces cerevisiae</i> Tomohiro Yorimitsu, Shadia Zaman, James R. Broach, Molecular Biology of the Cell MitophagyMolecular RegulationGeneticsRim15 KinaseCell Autophagy	2007	235
Glucose regulates transcription in yeast through a network of signaling pathways Shadia Zaman, Soyeon I. Lippman, Lisa Schneper, Molecular Systems Biology Transcriptional RegulationSignal TransductionGeneticsGene RegulationCellular Regulatory Mechanism	2009	225
The Tumor Suppressor Protein Menin Inhibits AKT Activation by Regulating Its Cellular Localization Yan Wang, Atsushi Ozawa, Shadia Zaman, Cancer Research Tumor BiologySystems BiologySignal TransductionMenin ExpressionCell Regulation	2010	112
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer Asma Dilawari, Mirat Shah, Gwynn Ison, Clinical Cancer Research	2023	93
Glucose regulates transcription in yeast through a network of signaling pathways Shadia Zaman, Soyeon I. Lippman, Lisa Schneper, Molecular Systems Biology Transcriptional RegulationSignal TransductionGeneticsGene RegulationCellular Regulatory Mechanism	2009	27
Linking MedDRA®-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors Sirarat Sarntivijai, Shelley Zhang, Desikan Jagannathan, Drug Safety Adverse EventsDrug DiscoveryPharmacologyPathologyMeddra®-coded Clinical Phenotypes	2016	24
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma Muhamed Baljević, Shadia Zaman, Veerabhadran Baladandayuthapani, Annals of Hematology	2017	24
Dengue Infection in Children: Clinical Profile and Outcome in Dhaka City Kamrunnaher Shultana, A. Z. M. Motiur Rahman, Abdullah Al Baki, American Journal of Pediatrics Vector-borne PathogenDengue Shock SyndromeMalariaClinical EpidemiologyPediatrics	2019	23
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines Cornel J. Phillip, Shadia Zaman, Shujun Shentu, Journal of Hematology & Oncology	2013	22
Targeting the Pro-Survival Protein MET with Tivantinib (ARQ 197) Inhibits Growth of Multiple Myeloma Cells Shadia Zaman, Shujun Shentu, Jing Yang, Neoplasia	2015	14

Page 1